Bruker Announces the Appointment of Thomas Bachmann as President of the Bruker BioSpin Group
August 19 2013 - 7:00AM
Business Wire
Bruker Corporation (NASDAQ: BRKR) today announced the
appointment of Mr. Thomas Bachmann as the new President of its
Bruker BioSpin Group. Mr. Bachmann most recently served as Chief
Executive Officer of Tecan Group in Switzerland, a leading global
provider of complex laboratory instrumentation and integrated
liquid-handling workflow solutions for life science research and
diagnostics.
Thomas Bachmann (Photo: Business
Wire)
The Bruker BioSpin Group is the global market and technology
leader in analytical and preclinical magnetic resonance
instrumentation, with major operations in Germany, Switzerland,
France and the United States, as well as numerous applications and
customer service centers around the world. The Bruker BioSpin Group
operates in two divisions:
- Magnetic Resonance Spectroscopy (MRS)
division, consisting of the three business units nuclear magnetic
resonance (NMR), electron paramagnetic resonance (EPR) and compact
magnetic resonance (CMR)
- Preclinical Imaging (PCI) division,
consisting of the preclinical imaging product lines magnetic
resonance imaging (MRI), magnetic particle imaging (MPI), X-ray
micro-CT, as well as optical and PET/SPECT/CT molecular
imaging.
Frank Laukien, Bruker’s President and Chief Executive Officer,
stated: “I am very pleased to welcome Thomas Bachmann to Bruker.
His life-science background and his broad management experience
will allow him to lead our excellent BioSpin management team in
order to further accelerate our innovation, profitable growth and
operational excellence initiatives. Thomas will be a valuable
addition for all of Bruker due to his diversified industrial
experience, his global customer and operations exposure, and his
successful track record.”
“Bruker is a premier brand in our analytical, life-science and
diagnostic instruments industry, and an exceptional company that I
have come to know well over the past few years,” said Thomas
Bachmann. “I am delighted to join Bruker, and together with an
experienced management team I look forward to further developing
the Bruker BioSpin Group. With emphasis on innovation for
customers, applications development and market expansion, paired
with operational excellence and margin expansion, Bruker BioSpin
has significant value creation potential over the years to
come.”
Thomas Bachmann brings over twenty-five years of global
experience in sales and marketing, in leading and transforming
complex businesses, as well as in strategy and business development
to his new role as Bruker BioSpin Group President, including
experience as a CEO of two publicly traded companies. From 2005
until 2012, Mr. Bachmann served as CEO of Tecan Group, where he
increased operational effectiveness, expanded into new businesses,
developed emerging markets, created a solid organization,
established regulatory competence and compliance, grew
profitability and built a strong balance sheet. From 2002 until
2004, he was CEO of the Arbonia-Forster Group’s Steel Systems
Business, a global provider of building supplies. From 1985 until
2002, Mr. Bachmann served in various roles as global Sales and
Marketing Director, Business Unit Director and Senior Vice
President of Corporate Development at Rieter Holding, a global
provider of textile machinery and plants, as well as an automotive
supplier of acoustic- and thermal insulation systems. Mr. Bachmann
holds a B.Sc. in Mechanical Engineering and an Executive MBA from
IMD Business School in Switzerland.
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of high
performance scientific instruments and solutions for molecular and
materials research, as well as industrial, diagnostics and applied
analysis.
For more information, please visit www.bruker.com
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130819005124/en/
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024